Personalis Revenue and Competitors

Claim your profile



Total Funding



Estimated Revenue & Valuation

  • Personalis's estimated annual revenue is currently $57.7M per year.(i)
  • Personalis received $33.0M in venture funding in January 2015.
  • Personalis's estimated revenue per employee is $129,573
  • Personalis's total funding is $225.1M.

Employee Data

  • Personalis has 445 Employees.(i)
  • Personalis grew their employee count by 31% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

Personalis, Inc. is partnering with biopharma to develop and commercialize the next generation of cancer immunotherapies. We provide advanced genomic sequencing and analytics for immuno-oncology. Our patented ACE (Accuracy and Content Enhanced) Technology forms the foundation of all Personalis products and makes it possible for us to achieve augmented coverage of difficult-to-sequence genomic regions often missed with the use of conventional sequencing techniques, for more comprehensive and accurate genomic data. ACE ImmunoID, our universal platform for immuno-oncology, combines augmented whole exome and transcriptome assays with analytics that capture neoantigens, elucidate the tumor microenviroment, and identify mechanisms of tumor escape. The company's Clinical Laboratory is GxP aligned as well as CLIA88 and CAP accredited. To learn more, visit us at and follow us on Twitter @personalisinc.

keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Personalis News

2022-04-17 - Personalis Announces Issuance of Additional US Patent ...

Overall, Personalis has 19 issued US and foreign patents, spanning 16 distinct families, relating to advanced genomic sequencing and analysis...

2022-04-17 - Personalis Publishes New Data Demonstrating Highly ...

Personalis Publishes New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA Gene. Tool detects...

2022-04-13 - Personalis and Merck KGaA, Darmstadt, Germany to Present ...

Personalis and Merck KGaA, Darmstadt, Germany to Present Comprehensive Tumor Subtyping Collaboration Data at AACR Annual Meeting 2022. Profiling...

2019-09-08 - Personalis Q2 Revenues Up 80 Percent

NEW YORK – Cancer sequencing firm Personalis reported after the close of the market on Tuesday that its second quarter 2019 revenues were ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Personalis Funding

DateAmountRoundLead InvestorsReference
2015-01-14$33.0MCLightspeed Venture PartnersArticle